Insider Trading Arrangements |
3 Months Ended | 6 Months Ended |
|---|---|---|
|
Jun. 30, 2024
shares
|
Jun. 30, 2024
shares
|
|
| Trading Arrangements, by Individual | ||
| Non-Rule 10b5-1 Arrangement Adopted | false | |
| Rule 10b5-1 Arrangement Terminated | false | |
| Non-Rule 10b5-1 Arrangement Terminated | false | |
| Kevin Fitzgerald [Member] | ||
| Trading Arrangements, by Individual | ||
| Material Terms of Trading Arrangement | Kevin Fitzgerald, Ph.D., Executive Vice President, Chief Scientific Officer On May 10, 2024, Kevin Fitzgerald, Ph.D., our Executive Vice President, Chief Scientific Officer, entered into a Rule 10b5-1 trading plan that provides that Dr. Fitzgerald, acting through a broker, may sell up to an aggregate of 50,634 shares of our common stock received upon the settlement of awards granted to Dr. Fitzgerald as equity incentive compensation, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur from August 11, 2024 to May 10, 2025. The plan is scheduled to terminate on May 10, 2025, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Dr. Fitzgerald or the broker, or as otherwise provided in the plan.
|
|
| Name | Kevin Fitzgerald | |
| Title | Executive Vice President, Chief Scientific Officer | |
| Rule 10b5-1 Arrangement Adopted | true | |
| Adoption Date | May 10, 2024 | |
| Expiration Date | May 10, 2025 | |
| Arrangement Duration | 365 days | |
| Aggregate Available | 50,634 | 50,634 |
| Dennis A. Ausiello [Member] | ||
| Trading Arrangements, by Individual | ||
| Material Terms of Trading Arrangement | Dennis A. Ausiello, M.D., Director On May 3, 2024, Dennis A. Ausiello, M.D., a member of our board of directors, entered into a Rule 10b5-1 trading plan that provides that Dr. Ausiello, acting through a broker, may sell up to an aggregate of 20,250 shares of our common stock received upon the exercise of options granted to Dr. Ausiello as director compensation, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur if the market price of our common stock is above specified prices from August 5, 2024 to May 20, 2025. The plan is scheduled to terminate on May 20, 2025, subject to earlier termination upon the sale of all shares subject to the plan upon termination by Dr. Ausiello or the broker, or as otherwise provided in the plan.
|
|
| Name | Dennis A. Ausiello | |
| Title | Director | |
| Rule 10b5-1 Arrangement Adopted | true | |
| Adoption Date | May 3, 2024 | |
| Expiration Date | May 20, 2025 | |
| Arrangement Duration | 382 days | |
| Aggregate Available | 20,250 | 20,250 |